Article

Signs of hypertensive retinopathy linked to risk of cardiovascular disease

Patients with moderate signs of hypertensive retinopathy should probably be evaluated for systemic microvascular diseases, noted Tien Y. Wong, MD, at the "Ocular Pathology&#8212Beyond the Eye" symposium at the Association for Research in Vision and Ophthalmology annual meeting.

May 2 - Fort Lauderdale, FL - Patients with moderate signs of hypertensive retinopathy should probably be evaluated for systemic microvascular diseases, noted Tien Y. Wong, MD, at the "Ocular Pathology-Beyond the Eye" symposium at the Association for Research in Vision and Ophthalmology annual meeting.

Specific signs to look for include generalized and focal retinal arteriolar narrowing, arterio-venous nicking, retinal hemorrhages, microaneurysms, and cotton wool spots, explained Dr. Wong, of the Centre for Eye Research Australia, University of Melbourne, Australia.

Clinicians should consider using a simple classification system of hypertensive retinopathy signs for evaluating the severity of the condition. He proposed four categories: none, mild, moderate, and malignant.

"Hypertensive retinopathy is common in the general population (ranging between 3% to 14%)," Dr. Wong said. "These hypertensive retinopathy signs are strongly associated with concurrent blood pressure levels."

However, these retinal changes can also be found in the normotensive population. "Some signs are predictive of future risk of hypertension and might be a marker of hypertension severity," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.